

# Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 591 • March 2016

## Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Apo-Linezolid 600 mg Tablet (DIN 02426552) manufactured by Apotex Inc., Sandoz Linezolid 600 mg Tablet (DIN 02422689) manufactured by Sandoz Canada Inc. and Zyvoxam 600 mg Tablet (DIN 02243684) manufactured by Pfizer Canada Inc., Zyvoxam 20 mg/ml Oral Suspension (DIN 02243686), manufactured by Pfizer Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Pfizer Canada Inc. has advised Alberta Blue Cross that the shortage of Zyvoxam 600 mg Tablet (DIN 02243684) has been resolved.

As a result, Zyvoxam 20 mg/ml Oral Suspension (DIN 02243686) will no longer be considered a temporary benefit for the *ADBL* after **March 8, 2016**.

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.591 2016/03

